• 1.

    Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I, 1993. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5: 5661.

    • Search Google Scholar
    • Export Citation
  • 2.

    Brady G, MacArthur GJ, Farrell PJ, 2007. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 60: 13971402.

  • 3.

    Bishop PC, Rao VK, Wilson WH, 2000. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 18: 574583.

  • 4.

    Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML, 2007. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer 120: 121127.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bornkamm GW, 2009. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer 124: 17451755.

    • Search Google Scholar
    • Export Citation
  • 6.

    Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E, 2007. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7: 166175.

    • Search Google Scholar
    • Export Citation
  • 7.

    Iversen OH, Iversen U, Ziegler JL, Bluming AZ, 1974. Cell kinetics in Burkitt lymphoma. Eur J Cancer 10: 155163.

  • 8.

    Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT, 2007. A molecular link between malaria and epstein-barr virus reactivation. PLoS Pathog 3: e80.

    • Search Google Scholar
    • Export Citation
  • 9.

    Epstein MA, 1984. Burkitt's lymphoma: clues to the role of malaria. Nature 312: 398.

  • 10.

    Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart S, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell R, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel J, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler H, Möller P, MacLeod R, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler P, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; MMML-Seq Project ICGC, 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 13161320.

    • Search Google Scholar
    • Export Citation
  • 11.

    Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards K, Dunphy C, Choi W, Srivastava G, Lugar P, Rizzieri D, Lagoo A, Bernal-Mizrachi L, Mann K, Flowers C, Naresh K, Evens A, Chadburn A, Gordon L, Czader M, Gill J, Hsi E, Greenough A, Moffitt A, McKinney M, Banerjee A, Grubor V, Levy S, Dunson D, Dave S, 2012. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 13211325.

    • Search Google Scholar
    • Export Citation
  • 12.

    Howell WM, Rose-Zerilli MJ, 2007. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137: 194S199S.

  • 13.

    Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G, 2004. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103: 35293534.

    • Search Google Scholar
    • Export Citation
  • 14.

    Cooper M, Caligiuri M, 2003. Cytokines and Cancer. The Cytokine Handbook (Fourth Edition). Elsevier Ltd., Academic Press, 12131232. ISBN: 978-0-12-689663-3.

    • Search Google Scholar
    • Export Citation
  • 15.

    Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD, 2005. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 174: 30153023.

    • Search Google Scholar
    • Export Citation
  • 16.

    Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N, 1990. Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunology 70: 100105.

    • Search Google Scholar
    • Export Citation
  • 17.

    Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PRA, White J, Jarrett RF, 2005. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 128: 493495.

    • Search Google Scholar
    • Export Citation
  • 18.

    Benjamin D, Knobloch TJ, Dayton MA, 1992. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 12891298.

    • Search Google Scholar
    • Export Citation
  • 19.

    Stewart JP, Behm FG, Arrand JR, Rooney CM, 1994. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200: 724732.

    • Search Google Scholar
    • Export Citation
  • 20.

    Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJL, 2003. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 44: 251255.

    • Search Google Scholar
    • Export Citation
  • 21.

    Liu J, Song B, Bai X, Liu W, Li Z, Wang J, Zheng Y, Wang Z, 2010. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 10: 456.

    • Search Google Scholar
    • Export Citation
  • 22.

    Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL, 2003. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88: 255259.

    • Search Google Scholar
    • Export Citation
  • 23.

    Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, Chen J, Yin C, 2011. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis 27: 305312.

    • Search Google Scholar
    • Export Citation
  • 24.

    Gourley IS, Kurtis JD, Kamoun M, Amon JJ, Duffy PE, 2002. Profound bias in interferon-γ and interleukin-6 allele frequencies in western Kenya, where severe malarial anemia is common in children. J Infect Dis 186: 10071012.

    • Search Google Scholar
    • Export Citation
  • 25.

    Baran W, Szepietowski JC, Mazur G, Baran E, 2008. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 88: 113116.

    • Search Google Scholar
    • Export Citation
  • 26.

    Ouma C, Davenport GC, Were T, Otieno MF, Hittner JB, Vulule JM, Martinson J, Ong'echa JM, Ferrell RE, Perkins DJ, 2008. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 124: 515524.

    • Search Google Scholar
    • Export Citation
  • 27.

    Burkitt D, 1962. A lymphoma syndrome in African children. Ann R Coll Surg Engl 30: 211219.

  • 28.

    Burkitt D, O'Conor G, 1961. Malignant lymphoma in African children. I. A clinical syndrome. Cancer 14: 258269.

  • 29.

    Cozen W, Gill PS, Ingles SA, Masood R, Martínez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM, 2004. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103: 32163221.

    • Search Google Scholar
    • Export Citation
  • 30.

    López RVM, Zago MA, Eluf-Neto J, Curado MP, Daudt AW, da Silva-Junior WA, Zanette DL, Levi JE, de Carvalho MB, Kowalski LP, Abrahão M, de Góis-Filho JF, Boffetta P, Wünsch-Filho V, 2011. Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6 gene polymorphisms in the survival of head and neck cancer. Braz J Med Biol Res 44: 10061012.

    • Search Google Scholar
    • Export Citation
  • 31.

    Mulama DH, Bailey JA, Foley J, Chelimo K, Ouma C, Jura WGZO, Otieno J, Vulule J, Moormann AM, 2014. Sickle cell trait is not associated with endemic Burkitt lymphoma: an ethnicity and malaria endemicity-matched case-control study suggests factors controlling EBV may serve as a predictive biomarker for this pediatric cancer. Int J Cancer 134: 645653.

    • Search Google Scholar
    • Export Citation
  • 32.

    Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R, 2005. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 191: 12331238.

    • Search Google Scholar
    • Export Citation
  • 33.

    Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford RA, Kazura JW, 2007. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 195: 799808.

    • Search Google Scholar
    • Export Citation
  • 34.

    Moormann AM, Lozada JS, 2009. Burkitt lymphoma in Uganda: 50 years of ongoing discovery. Pediatr Blood Cancer 52: 433434.

  • 35.

    Caligiuri MA, Lotze MT; SpringerLink, 2007. Cytokines in the Genesis and Treatment of Cancer. Totowa, NJ: Humana Press.

  • 36.

    Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY, 1996. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 54995505.

    • Search Google Scholar
    • Export Citation
  • 37.

    Mocellin S, Marincola FM, Young HA, 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 10431051.

  • 38.

    da Silva GN, Bacchi MM, Rainho Cu A, de Oliveira DE, 2007. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med 131: 16911696.

    • Search Google Scholar
    • Export Citation
  • 39.

    Minnicelli C, Barros MHM, Klumb CE, Romano SO, Zalcberg IR, Hassan R, 2012. Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS ONE 7: e46005.

    • Search Google Scholar
    • Export Citation
  • 40.

    Whittle HC, Brown J, Marsh K, Greenwood BM, Seidelin P, Tighe H, Wedderburn L, 1984. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312: 449450.

    • Search Google Scholar
    • Export Citation
  • 41.

    Tosato G, Tanner J, Jones KD, Revel M, Pike SE, 1990. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64: 30333041.

    • Search Google Scholar
    • Export Citation
  • 42.

    Tanner J, Tosato G, 1991. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239247.

    • Search Google Scholar
    • Export Citation
  • 43.

    Biron CA, Brossay L, 2001. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13: 458464.

  • 44.

    Helminen M, Lahdenpohja N, Hurme M, 1999. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 180: 496499.

    • Search Google Scholar
    • Export Citation
  • 45.

    Liu Y, de Waal Malefyt R, Briere F, Parham C, Bridon JM, Banchereau J, Moore KW, Xu J, 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 158: 604613.

    • Search Google Scholar
    • Export Citation
  • 46.

    Zeidler R, Eissner G, Meissner P, Uebel S, Tampé R, Lazis S, Hammerschmidt W, 1997. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90: 23902397.

    • Search Google Scholar
    • Export Citation
  • 47.

    Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM, 2008. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 123: 26582663.

    • Search Google Scholar
    • Export Citation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interleukin-6 and Interleukin-10 Gene Promoter Polymorphisms and Risk of Endemic Burkitt Lymphoma

View More View Less
  • Department of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya; Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya; Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts; Department of Medicine, Division of Transfusion, and Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, Massachusetts; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts

Overexpression of interleukin-6 (IL-6) and IL-10 in endemic Burkitt lymphoma (eBL) may facilitate tumorigenesis by providing a permissive cytokine milieu. Promoter polymorphisms influence interindividual differences in cytokine production. We hypothesized that children genetically predisposed for elevated cytokine levels may be more susceptible to eBL. Using case-control samples from western Kenya consisting of 117 eBL cases and 88 ethnically matched healthy controls, we tested for the association between eBL risk and IL-10 (rs1800896, rs1800871, and rs1800872) and IL-6 (rs1800795) promoter single nucleotide polymorphisms (SNPs) as well as IL-10 promoter haplotypes. In addition, the association between these variants and Epstein Barr Virus (EBV) load was examined. Results showed that selected IL-10 and IL-6 promoter SNPs and IL-10 promoter haplotypes were not associated with risk eBL or EBV levels in EBV-seropositive children. Findings from this study reveal that common variants within the IL-10 and IL-6 promoters do not independently increase eBL risk in this vulnerable population.

Author Notes

* Address correspondence to Ann M. Moormann, University of Massachusetts Medical School, 373 Plantation Street, Biotech 2, Suite 318, Worcester, MA 01605. E-mail: ann.moormann@umassmed.edu

Financial support: This work was supported by National Institutes of Health Grants 1KL2RR031981 (to J.A.B.), R01AI099473 (to J.A.B.), and R01CA134051 (to A.M.M.) and the Thrasher Research Fund (to A.M.M.).

Authors' addresses: Cliff I. Oduor and Collins Ouma, Department of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya, E-mails: cisayaoduor@gmail.com and collinouma@yahoo.com. Kiprotich Chelimo, Department of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya, and Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya, E-mail: chelimokiprotich@gmail.com. David H. Mulama and John Vulule, Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya, E-mails: dmulama@gmail.com and jvulule@gmail.com. Joslyn Foley, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, E-mail: joslyn.foley@umassmed.edu. Jeffrey A. Bailey, Department of Medicine, Division of Transfusion, and Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA, E-mail: jeffrey.bailey@umassmed.edu.

Save